Ionis Pharmaceuticals Q3 2026 earnings

IONS · 2026-11-09 07:00 BMO ET · 8-K on SEC · 10-Q on SEC

Revenue grew 15% YoY driven by commercial and R&D, but GAAP operating loss widened to $102M from a $140M profit.

Headline numbers

MetricActualYoYQoQ8-K location
Revenue$268M+15%—Ex. 99.1, income statement
EPS (GAAP)-$0.69-88.3%—Ex. 99.1, income statement
EPS (adjusted)-$0.70-154.5%—Ex. 99.1, income statement
Net income-$115M-192.7%—Ex. 99.1, income statement
Adj. EBITDA-$57M-133.5%—Ex. 99.1, income statement
Adj. EBITDA margin-21.3%-1.2 pp—Ex. 99.1, income statement

Revenue breakdown

SegmentActualYoYShare of revenueNote
Commercial revenue$119M+15%44%Product sales + Royalties
Research and development revenue$149M-57%56%Collaborative agreement revenue

Margins and costs

  • Gross margin 1.1% (prior 0.9%, change +0.2 pp)
  • Operating expenses $370M (+18.6% YoY)
  • One-offs in the quarter Interest expense related to the sale of future royalties: $18M; Interest expense related to the sale of future royalties: $35M (YTD)
  • Effective tax rate 0.9% (prior-year 0%, year-to-date 0.5%)
  • Non-GAAP bridge Excludes compensation expense related to equity awards and related tax effects. Compensation expense is non-cash.

KPIs

MetricActualPrior quarterPrior yearChange
Cash, cash equivalents and short-term investments$2,055M$2,677M$2,055M-$622M
Contracts receivable$59M$66M$59M-$7M
Total assets$2,995M$3,524M$2,995M-$529M

Guidance

MetricGuidePrior guideChange
Revenue$1.0B - $1.1B$1.0B - $1.1BNo change
Operating expenses$1.3B - $1.4B$1.3B - $1.4BNo change
Cash, cash equivalents and short-term investments$2.0B - $2.1B$2.0B - $2.1BNo change

What drove it

  • Revenue story Commercial revenue grew 15% YoY driven by DAWNZERA product sales; R&D revenue declined 57% YoY due to the absence of a $280M upfront payment received in Q2 2025.
  • EPS story GAAP EPS loss widened from $0.78 to -$0.69, primarily due to a $102M GAAP operating loss versus a $140M profit in the prior year.
  • One-off check Interest expense related to the sale of future royalties: $18M (Q3 2026) and $35M (YTD 2026).

The good

  • Commercial revenue grew 15% YoY driven by DAWNZERA product sales.
  • On track to achieve 2026 financial guidance.

The bad

  • Research and development revenue declined 57% YoY due to the absence of a $280M upfront payment received in Q2 2025.
  • GAAP operating loss widened to $102M from a $140M profit in the prior year.

The ugly

  • none

Open questions

  • What is the specific impact of the CARDIO-TTRansform study outcome on the eplontersen franchise?
  • What is the specific impact of the pelacarsen Lp(a) HORIZON cardiovascular outcomes trial results on the franchise?
  • What is the specific impact of the global launch of bepirovirsen for chronic hepatitis B on revenue?
  • What is the specific impact of the approval of zilganersen for Alexander disease on the franchise?
Full release

Ionis Pharmaceuticals (IONS) earnings release, November 9, 2026

Ionis Pharmaceuticals Inc (IONS) · Form 8-K, Item 2.02 · Filed · SEC filing

Attachments

Seq Document Description

───────────────────────────────────────────────────────────────────────────────

2 ef20085128_ex99-1.htm EXHIBIT 99.1

Financial statements

Income Statement

From the 10-Q · Three Months Ended — (Unaudited) (in thousands)

Three Months Ended – September 30, – 2026Three Months Ended – September 30, – 2025Nine Months Ended – September 30, – 2026Nine Months Ended – September 30, – 2025
Commercial revenue:
Product sales, net48,29632,530122,39058,091
Royalty revenue80,59275,694214,874209,811
Other commercial revenue7,3177,37425,37526,621
Total commercial revenue136,205115,598362,639294,523
Research and development revenue:
Collaborative agreement revenue102,77031,436356,567413,387
WAINUA joint development revenue3,7469,68537,55632,471
Total research and development revenue106,51641,121394,123445,858
Total revenue242,721156,719756,762740,381
Expenses:
Cost of sales3,3222,3389,0437,952
Research, development and patent215,878217,754643,158635,973
Selling, general and administrative154,22296,809454,977263,681
Total operating expenses373,422316,9011,107,178907,606
Loss from operations-130,701-160,182-350,416-167,225
Other income (expense):
Investment income19,54323,68265,25773,035
Interest expense-4,628-4,212-14,405-12,434
Interest expense related to sale of future royalties-4,129-17,952-38,972-55,422
Gain on investments, net9,52629,90821,9279,432
Other income, net277363805929
Loss before income tax benefit (expense)-110,112-128,393-315,804-151,685
Income tax benefit (expense)141-213-1,341-308
Net loss-109,971-128,606-317,145-151,993
Basic and diluted net loss per share-0.66-0.8-1.92-0.95
Shares used in computing basic and diluted net loss per share166,205159,765165,504159,216

Balance Sheet

From the 10-Q · September 30, — (in thousands, except share data)

September 30, – 2026 – (unaudited)December 31, – 2025
Current assets:
Cash and cash equivalents296,303372,260
Short-term investments1,587,6042,305,176
Contracts receivable88,34066,059
Inventories28,57810,048
Other current assets360,676237,092
Total current assets2,361,5012,990,635
Property, plant and equipment, net162,059123,048
Right-of-use assets228,035238,549
Deposits and other assets160,995171,604
Total assets2,912,5903,523,836
Current liabilities:
Accounts payable27,11328,082
Accrued compensation61,379116,236
Accrued liabilities116,177106,089
Income taxes payable1092,713
0 percent convertible senior notes due April 2026, net431,948
Liability related to sale of future royalties, net138,18811,689
Current portion of deferred contract revenue70,20373,761
Other current liabilities22,12311,049
Total current liabilities435,292781,567
Long-term deferred contract revenue48,75592,001
0 percent convertible senior notes due 2030, net754,289751,495
1.75 percent convertible senior notes due 2028, net569,974567,830
Liability related to sale of future royalties, net427,840551,353
Long-term lease liabilities262,477262,383
Long-term obligations20,32328,118
Total liabilities2,518,9503,034,747
Stockholders’ equity:
Common stock, $0.001 par value; 300,000,000 shares authorized, 166,410,425 and 163,304,875 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively166163
Additional paid-in capital3,381,6323,145,402
Accumulated other comprehensive loss-39,818-25,281
Accumulated deficit-2,948,340-2,631,195
Total stockholders' equity393,640489,089
Total liabilities and stockholders’ equity2,912,5903,523,836

Cash Flow

From the 10-Q · Nine Months Ended — (Unaudited) (in thousands)

Nine Months Ended – September 30, – 2026Nine Months Ended – September 30, – 2025
Operating activities:
Net loss-317,145-151,993
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation10,3336,749
Amortization of right-of-use operating lease assets10,5146,803
Amortization of other assets2,0961,801
Amortization of discount on investments, net-12,597-18,063
Amortization of debt issuance costs6,0454,940
Non-cash royalty revenue related to sale of royalties-35,986-38,478

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.